Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Sep;6(5):960-71.
doi: 10.1038/mi.2012.134. Epub 2013 Jan 16.

Inhibition of N-terminal ATPase on HSP90 attenuates colitis through enhanced Treg function

Affiliations

Inhibition of N-terminal ATPase on HSP90 attenuates colitis through enhanced Treg function

C B Collins et al. Mucosal Immunol. 2013 Sep.

Abstract

Inflammatory bowel disease (IBD) is a chronic inflammatory condition thought to reflect a failure of the enteral immune system to adequately regulate itself. Inflammatory stress drives upregulation of heat-shock proteins (HSPs), including the pro-inflammatory chaperone, HSP90. This protein sequesters the transcription factor, heat-shock factor 1 (HSF1) in the cytoplasm preventing transcription of a number of anti-inflammatory proteins. We hypothesized that inhibition of HSP90 would exert an anti-inflammatory effect and thereby attenuate intestinal inflammation in murine models of IBD. Inhibition of HSP90 with 17-allylaminogeldanamycin (17-AAG) reduced inflammation in acute dextran sodium sulfate and chronic CD45RB(High) colitis models coinciding with increased interleukin (IL)-10 production in the colon. Regulatory T cells (Tregs) from mice treated with 17-AAG demonstrated significantly greater suppressive capacity in vitro abolished in HSF1-/- or IL-10-/- cells. Finally, Tregs treated with 17-AAG exhibited increased nuclear localization of HSF1 with resultant upregulation of HSF1 response genes, including HSP70, HSP90 and IL-10.

PubMed Disclaimer

Figures

Figure 1
Figure 1
HSP90 inhibition attenuated chemically-induced murine colitis. (A) Weight loss of mice treated with vehicle or 17-AAG during DSS colitis. Mean % weight loss ± SEM from n≥8 mice, *P<0.05, **P<0.01. (B) Colon length (mm) of mice following DSS colitis measured postmortem, *P<0.05. (C) Histological evaluation of indices of inflammation (injury and inflammation) by a trained pathologist (PJ) in a blinded fashion, **P<0.01. (D) Representative micrographs of colonic H&E sections from mice each treatment group. Black scale bar indicates 100μm.
Figure 2
Figure 2
Altered cytokine profile from the inflamed colon following HSP90 inhibition. (A) Multiplex analysis of IL-2, IL-4, IL-10, IL-17, IFNγ and TNFα expression from 24hr culture of colonic explants from DSS colitic mice treated with 17-AAG. Mean ± SEM for n=4 individual mice, *P<0.05, ***P<0.001. (B) Representative zebra plot of CD4 T cells from the lamina propria of DSS colitic mice treated with vehicle or 17-AAG, showing expression of Foxp3. (C) Percentage of CD4+ T cells that are Foxp3+ from indicated organs of colitic mice. Mean ± SEM, n=3, *P<0.05, **P<0.01.
Figure 3
Figure 3
Protein expression and localization of HSP90 in the inflamed mouse colon compared with untreated controls. (A) Densitometric determination of HSP90 expression in colonic tissue from water-treated or DSS-treated mice, *P<0.05. (B) Representative western blot of HSP90 expression from water and DSS-treated mouse colonic homogenates. (C) Representative immunofluorescent micrographs showing staining for HSP90 in PE at 10× and 40× magnification at room temperature using a Zeiss Axio Imager A1 Microscope with Axiovision 4.6 acquisition software.
Figure 4
Figure 4
Heat shock-induced HSP90α and HSPβ expression on mouse Tregs. (A) Mean fluorescent intensity of HSP90α and HSP90β expression in permeabilized newly converted CD4+CD25+Foxp3+ Tregs compared with non-Tregs with(out) heat shock. Mean ± SEM, n=3, *P<0.05, **P<0.01, ***P<0.001. (B) Representative histograms of expression of HSP90α and HSP90β on permeabilized CD4+Foxp3+ (grey) or CD4+Foxp3Neg cells (white). (C) Mean fluorescent intensity of HSP90α and HSP90β expression in permeabilized newly converted CD4+CD25+Foxp3+ Tregs compared with non-Tregs with(out) heat shock. Mean ± SEM, n=3, **P<0.01, ***P<0.001. (D) Representative histograms of expression of HSP90α and HSP90β on permeabilized CD4+Foxp3+ from the colonic LP (grey), the spleen (dashed line) or CD4+Foxp3Neg cells (white).
Figure 5
Figure 5
HSP90 inhibition attenuates established adoptive-transfer colitis. (A) Weight-loss curve of RAG1−/− mice adoptively transferred CD45RBHigh cells treated with vehicle or 17-AAG upon establishment of disease, *P<0.05, ***P<0.001 (B) Postmortem measurement of colon length of CD45RBHigh cell recipient with(out) treatment with 17-AAG (40mg/kg/day). Mean ± SEM, **P<0.01. (C) Histological evaluation of indices of active and chronic inflammation in CD45RBHigh model of colitis by a trained pathologist in a blinded fashion. **P<0.01. (D) Representative micrographs of colonic H&E sections from mice each treatment group. Black scale bar indicates 100μm
Figure 6
Figure 6
HSP90 inhibition increases IL-10 production and Foxp3 expression in the inflamed colon. (A) Multiplex analysis of IFNγ, TNFα and IL-10 expression from 24hr culture of colonic explants from CD45RBHigh adoptive-transfer colitic mice treated with 17-AAG. Mean ± SEM for n=4 individual mice, **P<0.01, ***P<0.001. (B) Representative zebra plot of CD4+ T cells from the lamina propria of CD45RBHigh colitic mice treated with vehicle or 17-AAG, showing expression of Foxp3. (C) Percentage of CD4+ T cells that are Foxp3+ from indicated organs of colitic mice, *P<0.05. (D) Representative zebra plots of IL-10 expression in CD4+Foxp3+ Tregs isolated from the colonic LP of CD45RBHgh colitis. (E) Percentage of CD4+Foxp3+ IL-10+ Tregs following vehicle or 17-AAG (40mg/kg/day) treatment. Mean ± SEM, n≥4, *P<0.05, **P<0.01, ***P<0.001.
Figure 7
Figure 7
HSP90 inhibition enhances regulatory T cell function in vitro via HSF1. Representative histograms of CellTrace-labeled CD4+ T cells co-cultured with decreasing concentrations of CD4+CD25+ Tregs from HSF1+/+ vehicle-treated mice or HSF1+/+ and HSF1−/− mice treated with 17-AAG. Proliferation of CD3-stimulated CD4+ co-cultured with Tregs from vehicle or 17-AAG-treated mice. Results representative of N=3 individual experiments with similar results.
Figure 8
Figure 8
Enhancing suppressive function of 17-AAG is IL-10 dependent. Representative histograms of CellTrace-labeled CD4+ T cells co-cultured with decreasing concentrations of CD4+CD25+ Tregs from IL-10−/− mice treated with(out) 17-AAG. Results representative of N=3 individual experiments with similar results.
Figure 9
Figure 9
HSP90 inhibition increases HSF1 translocation and transcriptional activation. (A) Representative blot of HSF1 either denatured or non-denatured from Tregs stimulated for 6 h with CD3 and CD28 with(out) 17-AAG (250nM). (B) Realtime RT-PCR analysis of expression of HSP90 isoforms (aa1, ab1), HSP70 isoforms (HSPA1A, HSPA1B) and IL-10 mRNA from isolated activated Tregs treated for 6 or 24h with 17-AAG (250nM). Mean ± SEM, n=3, *P<0.05, **P<0.01.

Similar articles

Cited by

References

    1. Singh B, et al. Control of intestinal inflammation by regulatory T cells. Immunol Rev. 2001;182:190–200. - PubMed
    1. Mottet C, Uhlig HH, Powrie F. Cutting edge: cure of colitis by CD4+CD25+ regulatory T cells. J Immunol. 2003;170:3939–3943. - PubMed
    1. Duchmann R, et al. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD) Clin Exp Immunol. 1995;102:448–455. - PMC - PubMed
    1. de Zoeten EF, et al. Histone deacetylase 6 and heat shock protein 90 control the functions of foxp3+ T-regulatory cells. Mol Cell Biol. 2011;31:2066–2078. - PMC - PubMed
    1. De AK, Kodys KM, Yeh BS, Miller-Graziano C. Exaggerated human monocyte IL-10 concomitant to minimal TNF-alpha induction by heat-shock protein 27 (Hsp27) suggests Hsp27 is primarily an antiinflammatory stimulus. J Immunol. 2000;165:3951–3958. - PubMed

Publication types

MeSH terms